Annett Hessel | Principal Scientist

Annett Hessel, Principal Scientist, Pfizer

Annett Hessel, PhD obtained her MS in Biology from Faculty of Biosciences, Pharmacy and Psychology, at the University Leipzig in Germany (2006). Afterwards, she joined the Molecular Vaccines/Virology R&D group at Baxter and graduated with a PhD in Medical Science from the Medical University Vienna / Baxter (2011). Annett’s PhD studies involved the isolation of influenza genes and cloning into poxviruses and using recombinant viruses studied the humoral and cellular immune response based on different influenza proteins in mouse model. Annett continued to work at the Baxter Orth Molecular Vaccines group, where her work focused on recombinant Poxviruses, Influenza viruses and Flaviviruses. In 2014, Pfizer acquired the vaccine business from Baxter and Annett joined the Vaccines Analytical Development (MSAT) group where she was responsible for recombinant Flaviviruses, FSME small scale model development work, and development/improvement of various other bioassays (qPCR and ELISA). Since June 2017, Annett is leading the Vaccines Analytical Development group where she is responsible for a number of projects, e.g. development of an in vitro potency assay for FSME Immun®.


Pre-congress Workshops, April 6 @ 10:00


Analytical methods that ensure identity, purity, and potency of vaccines have continued to improve but are primarily used for characterization rather than release testing. USP Biologics will gather stakeholders to learn about novel methods and to discuss opportunities to advance these methods in both pharmaceutical QClabs as well as global control laboratories. The workshop will include talks as well as an expert panel to debate these topics and address questions from the audience.Workshop leader opening remarks: Dr Maura C. Kibbey, Senior Scientific Fellow, Education & Training, Global Biologics, USPPresenations topics include:
  • Use of NMR assays for characterization of polysaccharide-based vaccines
  • Opportunities and challenges of in vitro potency development for FSME Immun release and stability testing
  • A regulatory perspective on NGS for adventitious virus detection in biologics
  • Strategies and Examples for vaccine development and lifecycle management
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates